Search

Your search keyword '"Lehto, Kelli"' showing total 34 results
Start Over Author "Lehto, Kelli" Search Limiters Available in Library Collection

Refine your results

more »

more »

more »
34 results on '"Lehto, Kelli"'

1. Mental illness and COVID-19 vaccination: a multinational investigation of observational & register-based data

Author

Barker, Mary M., Kõiv, Kadri, Magnúsdóttir, Ingibjörg, Milbourn, Hannah, Wang, Bin, Du, Xinkai, Murphy, Gillian, Herweijer, Eva, Gísladóttir, Elísabet U., Li, Huiqi, Lovik, Anikó, Kähler, Anna K., Campbell, Archie, Feychting, Maria, Hauksdóttir, Arna, Joyce, Emily E., Thordardottir, Edda Bjork, Frans, Emma M., Hoffart, Asle, Mägi, Reedik, Tómasson, Gunnar, Ásbjörnsdóttir, Kristjana, Jakobsdóttir, Jóhanna, Andreassen, Ole A., Sullivan, Patrick F., Johnson, Sverre Urnes, Aspelund, Thor, Brandlistuen, Ragnhild Eek, Ask, Helga, McCartney, Daniel L., Ebrahimi, Omid V., Lehto, Kelli, Valdimarsdóttir, Unnur A., Nyberg, Fredrik, and Fang, Fang

Published
2024
Full Text
View/download PDF

6. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study

Author

Magnúsdóttir, Ingibjörg, Lovik, Anikó, Unnarsdóttir, Anna Bára, McCartney, Daniel, Ask, Helga, Kõiv, Kadri, Nordahl Christoffersen, Lea Arregui, Johnson, Sverre Urnes, McIntosh, Andrew, Kähler, Anna K., Campbell, Archie, Hauksdóttir, Arna, Fawns-Ritchie, Chloe, Erikstrup, Christian, Helenius, Dorte, Altschul, Drew, Thordardottir, Edda Bjork, Eyþórsson, Elías, Frans, Emma M., Tómasson, Gunnar, Jónsdóttir, Harpa Lind, Rúnarsdóttir, Harpa, Hjalgrim, Henrik, Harõardóttir, Hrönn, González-Hijón, Juan, Banasik, Karina, Dinh, Khoa Manh, Lu, Li, Milani, Lili, Trogstad, Lill, Didriksen, Maria, Ebrahimi, Omid V., Sullivan, Patrick F., Magnus, Per Minor, Shen, Qing, Nesvåg, Ragnar, Mägi, Reedik, Pálsson, Runólfur, Ostrowski, Sisse Rye, Werge, Thomas, Hoffart, Asle, Porteous, David J, Fang, Fang, Jakobsdóttir, Jóhanna, Lehto, Kelli, Andreassen, Ole A., Pedersen, Ole B.V., Aspelund, Thor, Valdimarsdóttir, Unnur Anna, Christoffersen, Lea Arregui Nordahl, Ebrahimi, Omid V, Andreassen, Ole A, and Pedersen, Ole B V

Published
2022
Full Text
View/download PDF

7. Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classes.

Author

Cordioli, Mattia, Corbetta, Andrea, Kariis, Hanna Maria, Jukarainen, Sakari, Vartiainen, Pekka, Kiiskinen, Tuomo, Ferro, Matteo, FinnGen, Perola, Markus, Ripatti, Samuli, Ganna, Andrea, Metspalu, Andres, Milani, Lili, Esko, Tõnu, Mägi, Reedik, Nelis, Mari, Hudjashov, Georgi, Niemi, Mikko, and Lehto, Kelli

Subjects
DRUG therapy, GENETIC correlations, PATIENT compliance, IMMIGRATION status, GENETIC variation
Abstract

Low drug adherence is a major obstacle to the benefits of pharmacotherapies and it is therefore important to identify factors associated with discontinuing or being poorly adherent to a prescribed treatment regimen. Using high-quality nationwide health registry data and genome-wide genotyping, we evaluate the impact of socio-demographic and genetic risk factors on adherence and persistence for 5 common medication classes that require long-term, regular therapy (N = 1,814,591 individuals from Finnish nationwide registries, 217,005 with genetic data from Finland and Estonia). Need for social assistance and immigration status show a notable negative effect on persistence and adherence across the examined medications (odd ratios between 0.48 and 0.82 for persistence and between 1.1% to 4.3% decrease in adherence) while demographic and health factors show comparably modest or inconsistent effects. A genome-wide scan does not identify genetic variants associated with the two phenotypes, while some pharmacogenes (i.e. CYP2C9 and SLCO1B1) are modestly associated with persistence, but not with adherence. We observe significant genetic correlations between medication adherence and participation in research studies. Overall, our findings suggest that socio-economically disadvantaged groups would benefit from targeted interventions to improve the dispensing and uptake of pharmacological treatments. This study examines socio-demographic and genetic factors for adherence and persistence to five medication classes, identifying lower socio-economic and immigration status as major predictors of lower adherence, while genetic factors show minimal impact. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Physical Activity, Suicidal Ideation, Suicide Attempt and Death Among Individuals With Mental or Other Medical Disorders : A Systematic Review of Observational Studies

Author

Fabiano, Nicholas, Gupta, Arnav, Wong, Stanley, Tran, Jason, Mohammad, Ibrahim Yz, Bal, Shan, Fiedorowicz, Jess G., Firth, Joseph, Stubbs, Brendon, Vancampfort, Davy, Schuch, Felipe B., Carr, Lucas J., Shorr, Risa, Cortese, Samuele, Manchia, Mirko, Hartman, Catharina A., Høye, Anne, Fusar-Poli, Paolo, Koyanagi, Ai, Vieta, Eduard, Nielsen, René Ernst, Holt, Richard Ig, Correll, Christoph U., Du Rietz, Ebba, Taipale, Heidi, Lehto, Kelli, Larsson, Henrik, Nordentoft, Merete, Dragioti, Elena, Skonieczna-Żydecka, Karolina, Solmi, Marco, Fabiano, Nicholas, Gupta, Arnav, Wong, Stanley, Tran, Jason, Mohammad, Ibrahim Yz, Bal, Shan, Fiedorowicz, Jess G., Firth, Joseph, Stubbs, Brendon, Vancampfort, Davy, Schuch, Felipe B., Carr, Lucas J., Shorr, Risa, Cortese, Samuele, Manchia, Mirko, Hartman, Catharina A., Høye, Anne, Fusar-Poli, Paolo, Koyanagi, Ai, Vieta, Eduard, Nielsen, René Ernst, Holt, Richard Ig, Correll, Christoph U., Du Rietz, Ebba, Taipale, Heidi, Lehto, Kelli, Larsson, Henrik, Nordentoft, Merete, Dragioti, Elena, Skonieczna-Żydecka, Karolina, and Solmi, Marco

Abstract

A growing body of research has demonstrated the potential role for physical activity as an intervention across mental and other medical disorders. However, the association between physical activity and suicidal ideation, attempts, and deaths has not been systematically appraised in clinical samples. We conducted a PRISMA 2020-compliant systematic review searching MEDLINE, EMBASE, and PsycINFO for observational studies investigating the influence of physical activity on suicidal behaviour up to December 6, 2023. Of 116 eligible full-text studies, seven (n=141691) were included. Depression was the most frequently studied c mental condition (43%, k=3), followed by chronic pain as the most common other medical condition (29%, k=2). Two case-control studies examined suicide attempts and found an association between physical activity and a reduced frequency of such attempts. However, in studies examining suicidal ideation (k=3) or suicide deaths (k=2), no consistent associations with physical activity were observed. Overall, our systematic review found that physical activity may be linked to a lower frequency of suicide attempts in non-prospective studies involving individuals with mental disorders., On behalf on ECNP Physical And meNtal (PAN-)Health group.

Published
2024
Full Text
View/download PDF

9. Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia : A systematic review and meta-analysis

Author

Solmi, Marco, Croatto, Giovanni, Fornaro, Michele, Schneider, Lynne Kolton, Rohani-Montez, S Christy, Fairley, Leanne, Smith, Nathalie, Bitter, István, Gorwood, Philip, Taipale, Heidi, Tiihonen, Jari, Cortese, Samuele, Dragioti, Elena, Rietz, Ebba Du, Nielsen, Rene Ernst, Firth, Joseph, Fusar-Poli, Paolo, Hartman, Catharina, Holt, Richard I. G., Høye, Anne, Koyanagi, Ai, Larsson, Henrik, Lehto, Kelli, Lindgren, Peter, Manchia, Mirko, Nordentoft, Merete, Skonieczna-Żydecka, Karolina, Stubbs, Brendon, Vancampfort, Davy, Boyer, Laurent, De Prisco, Michele, Vieta, Eduard, Correll, Christoph U., CNP Physical And meNtal Health Thematic Working Group (PAN-Health),, Solmi, Marco, Croatto, Giovanni, Fornaro, Michele, Schneider, Lynne Kolton, Rohani-Montez, S Christy, Fairley, Leanne, Smith, Nathalie, Bitter, István, Gorwood, Philip, Taipale, Heidi, Tiihonen, Jari, Cortese, Samuele, Dragioti, Elena, Rietz, Ebba Du, Nielsen, Rene Ernst, Firth, Joseph, Fusar-Poli, Paolo, Hartman, Catharina, Holt, Richard I. G., Høye, Anne, Koyanagi, Ai, Larsson, Henrik, Lehto, Kelli, Lindgren, Peter, Manchia, Mirko, Nordentoft, Merete, Skonieczna-Żydecka, Karolina, Stubbs, Brendon, Vancampfort, Davy, Boyer, Laurent, De Prisco, Michele, Vieta, Eduard, Correll, Christoph U., and CNP Physical And meNtal Health Thematic Working Group (PAN-Health),

Abstract

People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality. We included 135 studies from Europe (n = 70), North-America (n = 29), Asia (n = 33), Oceania (n = 2), Africa (n = 1). In incident plus prevalent schizophrenia, differences across continents emerged for all-cause mortality (highest in Africa, RR=5.98, 95 %C.I.=4.09-8.74, k = 1, lowest in North-America, RR=2.14, 95 %C.I.=1.92-2.38, k = 16), suicide (highest in Oceania, RR=13.5, 95 %C.I.=10.08-18.07, k = 1, lowest in North-America, RR=4.4, 95 %C.I.=4.07-4.76, k = 6), but not for natural-cause mortality. Europe had the largest association between antipsychotics and lower all-cause mortality/suicide (Asia had the smallest or no significant association, respectively), without differences for natural-cause mortality. Higher country socio-demographic index significantly moderated larger suicide-related and smaller natural-cause-related mortality risk in incident schizophrenia, with reversed associations in prevalent schizophrenia. Antipsychotics had a larger/smaller protective association in incident/prevalent schizophrenia regarding all-cause mortality, and smaller protective association for suicide-related mortality in prevalent schizophrenia. Additional regional differences emerged in incident schizophrenia, across countries, and secondary outcomes. Significant regional differences emerged for all-cause, cause-specific and suicide-related mortality. Natural-cause death was homogeneously increased globally. Moderators differed across countries. Glo, Unrestricted educational grant by Janssen Pharmaceuticals to Medscape.

Published
2024
Full Text
View/download PDF

10. Associations between attention-deficit hyperactivity disorder genetic liability and ICD-10 medical conditions in adults : utilizing electronic health records in a Phenome-Wide Association Study

Author

Haan, Elis, Krebs, Kristi, Võsa, Urmo, Brikell, Isabell, Larsson, Henrik, Lehto, Kelli, Haan, Elis, Krebs, Kristi, Võsa, Urmo, Brikell, Isabell, Larsson, Henrik, and Lehto, Kelli

Abstract

BACKGROUND: Attention-deficit hyperactivity disorder (ADHD) is often comorbid with other medical conditions in adult patients. However, ADHD is extremely underdiagnosed in adults and little is known about the medical comorbidities in undiagnosed adult individuals with high ADHD liability. In this study we investigated associations between ADHD genetic liability and electronic health record (EHR)-based ICD-10 diagnoses across all diagnostic categories, in individuals without ADHD diagnosis history. METHODS: We used data from the Estonian Biobank cohort (N = 111 261) and generated polygenic risk scores (PRS) for ADHD (PRSADHD) based on the ADHD genome-wide association study. We performed a phenome-wide association study (PheWAS) to test for associations between standardized PRSADHD and 1515 EHR-based ICD-10 diagnoses in the full and sex-stratified sample. We compared the observed significant ICD-10 associations to associations with (1) ADHD diagnosis and (2) questionnaire-based high ADHD risk analyses. RESULTS: After Bonferroni correction (p = 3.3 × 10-5) we identified 80 medical conditions associated with PRSADHD. The strongest evidence was seen with chronic obstructive pulmonary disease (OR 1.15, CI 1.11-1.18), obesity (OR 1.13, CI 1.11-1.15), and type 2 diabetes (OR 1.11, CI 1.09-1.14). Sex-stratified analysis generally showed similar associations in males and females. Out of all identified associations, 40% and 78% were also observed using ADHD diagnosis or questionnaire-based ADHD, respectively, as the predictor. CONCLUSIONS: Overall our findings indicate that ADHD genetic liability is associated with an increased risk of a substantial number of medical conditions in undiagnosed individuals. These results highlight the need for timely detection and improved management of ADHD symptoms in adults., This research in the Estonian Biobank was supported by the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012 GENTRANSMED and 2014-2020.4.01.16-0125), and the Estonian Research Council's grant No. PSG615. This study was also funded by EU H2020 grant 692145, Estonian Research Council Grant IUT20-60, IUT24-6. This research is also part of the TIMESPAN project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 965381. Henrik Larsson acknowledges financial support from the Swedish Research Council (2018-02599) and the Swedish Brain Foundation (FO2021-0115). Isabell Brikell acknowledges financial support from the Swedish Brain Foundation.

Published
2024
Full Text
View/download PDF

11. Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

Author

Nievergelt, Caroline M., Maihofer, Adam X., Atkinson, Elizabeth G., Chen, Chia Yen, Choi, Karmel W., Coleman, Jonathan R.I., Daskalakis, Nikolaos P., Duncan, Laramie E., Polimanti, Renato, Aaronson, Cindy, Amstadter, Ananda B., Andersen, Soren B., Andreassen, Ole A., Arbisi, Paul A., Ashley-Koch, Allison E., Austin, S. Bryn, Avdibegoviç, Esmina, Babić, Dragan, Bacanu, Silviu Alin, Baker, Dewleen G., Batzler, Anthony, Beckham, Jean C., Belangero, Sintia, Benjet, Corina, Bergner, Carisa, Bierer, Linda M., Biernacka, Joanna M., Bierut, Laura J., Bisson, Jonathan I., Boks, Marco P., Bolger, Elizabeth A., Brandolino, Amber, Breen, Gerome, Bressan, Rodrigo Affonseca, Bryant, Richard A., Bustamante, Angela C., Bybjerg-Grauholm, Jonas, Bækvad-Hansen, Marie, Børglum, Anders D., Børte, Sigrid, Cahn, Leah, Calabrese, Joseph R., Caldas-de-Almeida, Jose Miguel, Chatzinakos, Chris, Cheema, Sheraz, Clouston, Sean A.P., Colodro-Conde, Lucía, Coombes, Brandon J., Cruz-Fuentes, Carlos S., Dale, Anders M., Dalvie, Shareefa, Davis, Lea K., Deckert, Jürgen, Delahanty, Douglas L., Dennis, Michelle F., Desarnaud, Frank, DiPietro, Christopher P., Disner, Seth G., Docherty, Anna R., Domschke, Katharina, Dyb, Grete, Kulenović, Alma Džubur, Edenberg, Howard J., Evans, Alexandra, Fabbri, Chiara, Fani, Negar, Farrer, Lindsay A., Feder, Adriana, Feeny, Norah C., Flory, Janine D., Forbes, David, Franz, Carol E., Galea, Sandro, Garrett, Melanie E., Gelaye, Bizu, Gelernter, Joel, Geuze, Elbert, Gillespie, Charles F., Goleva, Slavina B., Gordon, Scott D., Goçi, Aferdita, Grasser, Lana Ruvolo, Guindalini, Camila, Haas, Magali, Hagenaars, Saskia, Hauser, Michael A., Heath, Andrew C., Hemmings, Sian M.J., Hesselbrock, Victor, Hickie, Ian B., Hogan, Kelleigh, Hougaard, David Michael, Huang, Hailiang, Huckins, Laura M., Hveem, Kristian, Jakovljević, Miro, Javanbakht, Arash, Jenkins, Gregory D., Johnson, Jessica, Jones, Ian, Jovanovic, Tanja, Karstoft, Karen Inge, Kaufman, Milissa L., Kennedy, James L., Kessler, Ronald C., Khan, Alaptagin, Kimbrel, Nathan A., King, Anthony P., Koen, Nastassja, Kotov, Roman, Kranzler, Henry R., Krebs, Kristi, Kremen, William S., Kuan, Pei Fen, Lawford, Bruce R., Lebois, Lauren A.M., Lehto, Kelli, Levey, Daniel F., Lewis, Catrin, Liberzon, Israel, Linnstaedt, Sarah D., Logue, Mark W., Lori, Adriana, Lu, Yi, Luft, Benjamin J., Lupton, Michelle K., Luykx, Jurjen J., Makotkine, Iouri, Maples-Keller, Jessica L., Marchese, Shelby, Marmar, Charles, Martin, Nicholas G., Martínez-Levy, Gabriela A., McAloney, Kerrie, McFarlane, Alexander, McLaughlin, Katie A., McLean, Samuel A., Medland, Sarah E., Mehta, Divya, Meyers, Jacquelyn, Michopoulos, Vasiliki, Mikita, Elizabeth A., Milani, Lili, Milberg, William, Miller, Mark W., Morey, Rajendra A., Morris, Charles Phillip, Mors, Ole, Mortensen, Preben Bo, Mufford, Mary S., Nelson, Elliot C., Nordentoft, Merete, Norman, Sonya B., Nugent, Nicole R., O’Donnell, Meaghan, Orcutt, Holly K., Pan, Pedro M., Panizzon, Matthew S., Pathak, Gita A., Peters, Edward S., Peterson, Alan L., Peverill, Matthew, Pietrzak, Robert H., Polusny, Melissa A., Porjesz, Bernice, Powers, Abigail, Qin, Xue Jun, Ratanatharathorn, Andrew, Risbrough, Victoria B., Roberts, Andrea L., Rothbaum, Alex O., Rothbaum, Barbara O., Roy-Byrne, Peter, Ruggiero, Kenneth J., Rung, Ariane, Runz, Heiko, Rutten, Bart P.F., de Viteri, Stacey Saenz, Salum, Giovanni Abrahão, Sampson, Laura, Sanchez, Sixto E., Santoro, Marcos, Seah, Carina, Seedat, Soraya, Seng, Julia S., Shabalin, Andrey, Sheerin, Christina M., Silove, Derrick, Smith, Alicia K., Smoller, Jordan W., Sponheim, Scott R., Stein, Dan J., Stensland, Synne, Stevens, Jennifer S., Sumner, Jennifer A., Teicher, Martin H., Thompson, Wesley K., Tiwari, Arun K., Trapido, Edward, Uddin, Monica, Ursano, Robert J., Valdimarsdóttir, Unnur, Van Hooff, Miranda, Vermetten, Eric, Vinkers, Christiaan H., Voisey, Joanne, Wang, Yunpeng, Wang, Zhewu, Waszczuk, Monika, Weber, Heike, Wendt, Frank R., Werge, Thomas, Williams, Michelle A., Williamson, Douglas E., Winsvold, Bendik S., Winternitz, Sherry, Wolf, Christiane, Wolf, Erika J., Xia, Yan, Xiong, Ying, Yehuda, Rachel, Young, Keith A., Young, Ross Mc D., Zai, Clement C., Zai, Gwyneth C., Zervas, Mark, Zhao, Hongyu, Zoellner, Lori A., Zwart, John Anker, deRoon-Cassini, Terri, van Rooij, Sanne J.H., van den Heuvel, Leigh L., Stein, Murray B., Ressler, Kerry J., Koenen, Karestan C., Nievergelt, Caroline M., Maihofer, Adam X., Atkinson, Elizabeth G., Chen, Chia Yen, Choi, Karmel W., Coleman, Jonathan R.I., Daskalakis, Nikolaos P., Duncan, Laramie E., Polimanti, Renato, Aaronson, Cindy, Amstadter, Ananda B., Andersen, Soren B., Andreassen, Ole A., Arbisi, Paul A., Ashley-Koch, Allison E., Austin, S. Bryn, Avdibegoviç, Esmina, Babić, Dragan, Bacanu, Silviu Alin, Baker, Dewleen G., Batzler, Anthony, Beckham, Jean C., Belangero, Sintia, Benjet, Corina, Bergner, Carisa, Bierer, Linda M., Biernacka, Joanna M., Bierut, Laura J., Bisson, Jonathan I., Boks, Marco P., Bolger, Elizabeth A., Brandolino, Amber, Breen, Gerome, Bressan, Rodrigo Affonseca, Bryant, Richard A., Bustamante, Angela C., Bybjerg-Grauholm, Jonas, Bækvad-Hansen, Marie, Børglum, Anders D., Børte, Sigrid, Cahn, Leah, Calabrese, Joseph R., Caldas-de-Almeida, Jose Miguel, Chatzinakos, Chris, Cheema, Sheraz, Clouston, Sean A.P., Colodro-Conde, Lucía, Coombes, Brandon J., Cruz-Fuentes, Carlos S., Dale, Anders M., Dalvie, Shareefa, Davis, Lea K., Deckert, Jürgen, Delahanty, Douglas L., Dennis, Michelle F., Desarnaud, Frank, DiPietro, Christopher P., Disner, Seth G., Docherty, Anna R., Domschke, Katharina, Dyb, Grete, Kulenović, Alma Džubur, Edenberg, Howard J., Evans, Alexandra, Fabbri, Chiara, Fani, Negar, Farrer, Lindsay A., Feder, Adriana, Feeny, Norah C., Flory, Janine D., Forbes, David, Franz, Carol E., Galea, Sandro, Garrett, Melanie E., Gelaye, Bizu, Gelernter, Joel, Geuze, Elbert, Gillespie, Charles F., Goleva, Slavina B., Gordon, Scott D., Goçi, Aferdita, Grasser, Lana Ruvolo, Guindalini, Camila, Haas, Magali, Hagenaars, Saskia, Hauser, Michael A., Heath, Andrew C., Hemmings, Sian M.J., Hesselbrock, Victor, Hickie, Ian B., Hogan, Kelleigh, Hougaard, David Michael, Huang, Hailiang, Huckins, Laura M., Hveem, Kristian, Jakovljević, Miro, Javanbakht, Arash, Jenkins, Gregory D., Johnson, Jessica, Jones, Ian, Jovanovic, Tanja, Karstoft, Karen Inge, Kaufman, Milissa L., Kennedy, James L., Kessler, Ronald C., Khan, Alaptagin, Kimbrel, Nathan A., King, Anthony P., Koen, Nastassja, Kotov, Roman, Kranzler, Henry R., Krebs, Kristi, Kremen, William S., Kuan, Pei Fen, Lawford, Bruce R., Lebois, Lauren A.M., Lehto, Kelli, Levey, Daniel F., Lewis, Catrin, Liberzon, Israel, Linnstaedt, Sarah D., Logue, Mark W., Lori, Adriana, Lu, Yi, Luft, Benjamin J., Lupton, Michelle K., Luykx, Jurjen J., Makotkine, Iouri, Maples-Keller, Jessica L., Marchese, Shelby, Marmar, Charles, Martin, Nicholas G., Martínez-Levy, Gabriela A., McAloney, Kerrie, McFarlane, Alexander, McLaughlin, Katie A., McLean, Samuel A., Medland, Sarah E., Mehta, Divya, Meyers, Jacquelyn, Michopoulos, Vasiliki, Mikita, Elizabeth A., Milani, Lili, Milberg, William, Miller, Mark W., Morey, Rajendra A., Morris, Charles Phillip, Mors, Ole, Mortensen, Preben Bo, Mufford, Mary S., Nelson, Elliot C., Nordentoft, Merete, Norman, Sonya B., Nugent, Nicole R., O’Donnell, Meaghan, Orcutt, Holly K., Pan, Pedro M., Panizzon, Matthew S., Pathak, Gita A., Peters, Edward S., Peterson, Alan L., Peverill, Matthew, Pietrzak, Robert H., Polusny, Melissa A., Porjesz, Bernice, Powers, Abigail, Qin, Xue Jun, Ratanatharathorn, Andrew, Risbrough, Victoria B., Roberts, Andrea L., Rothbaum, Alex O., Rothbaum, Barbara O., Roy-Byrne, Peter, Ruggiero, Kenneth J., Rung, Ariane, Runz, Heiko, Rutten, Bart P.F., de Viteri, Stacey Saenz, Salum, Giovanni Abrahão, Sampson, Laura, Sanchez, Sixto E., Santoro, Marcos, Seah, Carina, Seedat, Soraya, Seng, Julia S., Shabalin, Andrey, Sheerin, Christina M., Silove, Derrick, Smith, Alicia K., Smoller, Jordan W., Sponheim, Scott R., Stein, Dan J., Stensland, Synne, Stevens, Jennifer S., Sumner, Jennifer A., Teicher, Martin H., Thompson, Wesley K., Tiwari, Arun K., Trapido, Edward, Uddin, Monica, Ursano, Robert J., Valdimarsdóttir, Unnur, Van Hooff, Miranda, Vermetten, Eric, Vinkers, Christiaan H., Voisey, Joanne, Wang, Yunpeng, Wang, Zhewu, Waszczuk, Monika, Weber, Heike, Wendt, Frank R., Werge, Thomas, Williams, Michelle A., Williamson, Douglas E., Winsvold, Bendik S., Winternitz, Sherry, Wolf, Christiane, Wolf, Erika J., Xia, Yan, Xiong, Ying, Yehuda, Rachel, Young, Keith A., Young, Ross Mc D., Zai, Clement C., Zai, Gwyneth C., Zervas, Mark, Zhao, Hongyu, Zoellner, Lori A., Zwart, John Anker, deRoon-Cassini, Terri, van Rooij, Sanne J.H., van den Heuvel, Leigh L., Stein, Murray B., Ressler, Kerry J., and Koenen, Karestan C.

Abstract

Post-traumatic stress disorder (PTSD) genetics are characterized by lower discoverability than most other psychiatric disorders. The contribution to biological understanding from previous genetic studies has thus been limited. We performed a multi-ancestry meta-analysis of genome-wide association studies across 1,222,882 individuals of European ancestry (137,136 cases) and 58,051 admixed individuals with African and Native American ancestry (13,624 cases). We identified 95 genome-wide significant loci (80 new). Convergent multi-omic approaches identified 43 potential causal genes, broadly classified as neurotransmitter and ion channel synaptic modulators (for example, GRIA1, GRM8 and CACNA1E), developmental, axon guidance and transcription factors (for example, FOXP2, EFNA5 and DCC), synaptic structure and function genes (for example, PCLO, NCAM1 and PDE4B) and endocrine or immune regulators (for example, ESR1, TRAF3 and TANK). Additional top genes influence stress, immune, fear and threat-related processes, previously hypothesized to underlie PTSD neurobiology. These findings strengthen our understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation., Post-traumatic stress disorder (PTSD) genetics are characterized by lower discoverability than most other psychiatric disorders. The contribution to biological understanding from previous genetic studies has thus been limited. We performed a multi-ancestry meta-analysis of genome-wide association studies across 1,222,882 individuals of European ancestry (137,136 cases) and 58,051 admixed individuals with African and Native American ancestry (13,624 cases). We identified 95 genome-wide significant loci (80 new). Convergent multi-omic approaches identified 43 potential causal genes, broadly classified as neurotransmitter and ion channel synaptic modulators (for example, GRIA1, GRM8 and CACNA1E), developmental, axon guidance and transcription factors (for example, FOXP2, EFNA5 and DCC), synaptic structure and function genes (for example, PCLO, NCAM1 and PDE4B) and endocrine or immune regulators (for example, ESR1, TRAF3 and TANK). Additional top genes influence stress, immune, fear and threat-related processes, previously hypothesized to underlie PTSD neurobiology. These findings strengthen our understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation.

Published
2024

12. COVID-19 illness severity and 2-year prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and Denmark

Author

Shen, Qing, primary, Joyce, Emily E., additional, Ebrahimi, Omid V., additional, Didriksen, Maria, additional, Lovik, Anikó, additional, Sævarsdóttir, Karen Sól, additional, Magnúsdóttir, Ingibjörg, additional, Mikkelsen, Dorte Helenius, additional, Unnarsdóttir, Anna Bára, additional, Hauksdóttir, Arna, additional, Hoffart, Asle, additional, Kähler, Anna K., additional, Thórdardóttir, Edda Björk, additional, Eythórsson, Elías, additional, Frans, Emma M., additional, Tómasson, Gunnar, additional, Ask, Helga, additional, Hardardóttir, Hrönn, additional, Jakobsdóttir, Jóhanna, additional, Lehto, Kelli, additional, Lu, Li, additional, Andreassen, Ole A., additional, Sullivan, Patrick F., additional, Pálsson, Runólfur, additional, Erikstrup, Christian, additional, Ostrowski, Sisse Rye, additional, Werge, Thomas, additional, Aspelund, Thor, additional, Pedersen, Ole B.V., additional, Johnson, Sverre Urnes, additional, Fang, Fang, additional, and Valdimarsdóttir, Unnur Anna, additional

Published
2023
Full Text
View/download PDF

13. Estonian National Mental Health Study: Design and methods for a registry‐linked longitudinal survey

Author

Laidra, Kaia, primary, Reile, Rainer, additional, Havik, Merle, additional, Leinsalu, Mall, additional, Murd, Carolina, additional, Tulviste, Jaan, additional, Tamson, Merili, additional, Akkermann, Kirsti, additional, Kreegipuu, Kairi, additional, Sultson, Hedvig, additional, Ainsaar, Mare, additional, Uusberg, Andero, additional, Rahno, Jaana, additional, Panov, Liisi, additional, Leetmaa, Kadri, additional, Aasa, Anto, additional, Veidebaum, Toomas, additional, Lehto, Kelli, additional, and Konstabel, Kenn, additional

Published
2023
Full Text
View/download PDF

15. COVID-19 illness severity and 2-year prevalence of physical symptoms:an observational study in Iceland, Sweden, Norway and Denmark

Author

Shen, Qing, Joyce, Emily E., Ebrahimi, Omid V., Didriksen, Maria, Lovik, Anikó, Sævarsdóttir, Karen Sól, Magnúsdóttir, Ingibjörg, Mikkelsen, Dorte Helenius, Unnarsdóttir, Anna Bára, Hauksdóttir, Arna, Hoffart, Asle, Kähler, Anna K., Thórdardóttir, Edda Björk, Eythórsson, Elías, Frans, Emma M., Tómasson, Gunnar, Ask, Helga, Hardardóttir, Hrönn, Jakobsdóttir, Jóhanna, Lehto, Kelli, Lu, Li, Andreassen, Ole A., Sullivan, Patrick F., Pálsson, Runólfur, Erikstrup, Christian, Ostrowski, Sisse Rye, Werge, Thomas, Aspelund, Thor, Pedersen, Ole B. V., Johnson, Sverre Urnes, Fang, Fang, Valdimarsdóttir, Unnur Anna, Shen, Qing, Joyce, Emily E., Ebrahimi, Omid V., Didriksen, Maria, Lovik, Anikó, Sævarsdóttir, Karen Sól, Magnúsdóttir, Ingibjörg, Mikkelsen, Dorte Helenius, Unnarsdóttir, Anna Bára, Hauksdóttir, Arna, Hoffart, Asle, Kähler, Anna K., Thórdardóttir, Edda Björk, Eythórsson, Elías, Frans, Emma M., Tómasson, Gunnar, Ask, Helga, Hardardóttir, Hrönn, Jakobsdóttir, Jóhanna, Lehto, Kelli, Lu, Li, Andreassen, Ole A., Sullivan, Patrick F., Pálsson, Runólfur, Erikstrup, Christian, Ostrowski, Sisse Rye, Werge, Thomas, Aspelund, Thor, Pedersen, Ole B. V., Johnson, Sverre Urnes, Fang, Fang, and Valdimarsdóttir, Unnur Anna

Abstract

Background: Although the persistence of physical symptoms after SARS-CoV-2 infection is a major public health concern, evidence from large observational studies beyond one year post diagnosis remain scarce. We aimed to assess the prevalence of physical symptoms in relation to acute illness severity up to more than 2-years after diagnosis of COVID-19. Methods: This multinational study included 64,880 adult participants from Iceland, Sweden, Denmark, and Norway with self-reported data on COVID-19 and physical symptoms from April 2020 to August 2022. We compared the prevalence of 15 physical symptoms, measured by the Patient Health Questionnaire (PHQ-15), among individuals with or without a confirmed COVID-19 diagnosis, by acute illness severity, and by time since diagnosis. We additionally assessed the change in symptoms in a subset of Swedish adults with repeated measures, before and after COVID-19 diagnosis. Findings: During up to 27 months of follow-up, 34.5% participants (22,382/64,880) were diagnosed with COVID-19. Individuals who were diagnosed with COVID-19, compared to those not diagnosed, had an overall 37% higher prevalence of severe physical symptom burden (PHQ-15 score ≥15, adjusted prevalence ratio [PR] 1.37 [95% confidence interval [CI] 1.23–1.52]). The prevalence was associated with acute COVID-19 severity: individuals bedridden for seven days or longer presented with the highest prevalence (PR 2.25 [1.85–2.74]), while individuals never bedridden presented with similar prevalence as individuals not diagnosed with COVID-19 (PR 0.92 [0.68–1.24]). The prevalence was statistically significantly elevated among individuals diagnosed with COVID-19 for eight of the fifteen measured symptoms: shortness of breath, chest pain, dizziness, heart racing, headaches, low energy/fatigue, trouble sleeping, and back pain. The analysis of repeated measurements rendered similar results as the main analysis. Interpretation: These data suggest an elevated prevalence of som

Published
2023

16. Estonian National Mental Health Study : Design and methods for a registry‐linked longitudinal survey

Author

Laidra, Kaia, Reile, Rainer, Havik, Merle, Leinsalu, Mall, Murd, Carolina, Tulviste, Jaan, Tamson, Merili, Akkermann, Kirsti, Kreegipuu, Kairi, Sultson, Hedvig, Ainsaar, Mare, Uusberg, Andero, Rahno, Jaana, Panov, Liisi, Leetmaa, Kadri, Aasa, Anto, Veidebaum, Toomas, Lehto, Kelli, Konstabel, Kenn, Laidra, Kaia, Reile, Rainer, Havik, Merle, Leinsalu, Mall, Murd, Carolina, Tulviste, Jaan, Tamson, Merili, Akkermann, Kirsti, Kreegipuu, Kairi, Sultson, Hedvig, Ainsaar, Mare, Uusberg, Andero, Rahno, Jaana, Panov, Liisi, Leetmaa, Kadri, Aasa, Anto, Veidebaum, Toomas, Lehto, Kelli, and Konstabel, Kenn

Abstract

Objectives The Estonian National Mental Health Study (EMHS) was conducted in 2021–2022 to provide population-wide data on mental health in the context of COVID-19 pandemic. The main objective of this paper is to describe the rationale, design, and methods of the EMHS and to evaluate the survey response. Methods Regionally representative stratified random sample of 20,000 persons aged 15 years and older was drawn from the Estonian Population Register for the study. Persons aged 18 years and older at the time of the sampling were enrolled into three survey waves where they were invited to complete an online or postal questionnaire about mental well-being and disorders, and behavioral, cognitive, and other risk factors. Persons younger than 18 years of age were invited to fill an anonymous online questionnaire starting from wave 2. To complement and validate survey data, data on socio-demographic, health-related, and environmental variables were collected from six national administrative databases and registries. Additionally, a subsample was enrolled into a validation study using ecological momentary assessment. Results In total, 5636 adults participated in the survey wave 1, 3751 in wave 2, and 4744 in wave 3. Adjusted response rates were 30.6%, 21.1%, and 27.6%, respectively. Women and older age groups were more likely to respond. Throughout the three survey waves, a considerable share of adult respondents screened positive for depression (27.6%, 25.1%, and 25.6% in waves 1, 2, and 3, respectively). Women and young adults aged 18 to 29 years had the highest prevalence of depression symptoms. Conclusions The registry-linked longitudinal EMHS dataset comprises a rich and trustworthy data source to allow in-depth analysis of mental health outcomes and their correlates among the Estonian population. The study serves as an evidence base for planning mental health policies and prevention measures for possible future crises.

Published
2023
Full Text
View/download PDF

17. Comorbidity of atopic diseases and gastro-oesophageal reflux evidence of a shared cause

Author

Brew, Bronwyn K., Almqvist, Catarina, Lundholm, Cecilia, Andreasson, Anna, Lehto, Kelli, Talley, Nicholas J., Gong, Tong, Brew, Bronwyn K., Almqvist, Catarina, Lundholm, Cecilia, Andreasson, Anna, Lehto, Kelli, Talley, Nicholas J., and Gong, Tong

Abstract

Introduction: Gastro-oesophageal reflux disease (GERD) is the most common non-allergic comorbidity in adults with asthma; however, comorbidity with other atopic diseases such as eczema and hay fever is unclear. The objective was to assess the comorbidity of GERD with asthma and atopic diseases and to investigate possible mechanisms, including genetic and/or affective factors. Methods: A co-twin control study harnessing 46 583 adult twins. Questionnaires on health status were linked to national patient and prescribed drug register data. Analyses tested associations of comorbidity between multiple definitions of atopic diseases (self-report and register-based) with GERD. Comparisons were made between unpaired, monozygotic (MZ) and dizygotic (DZ) twins to assess genetic liability. Affective traits (depression, anxiety and neuroticism) were added to models as possible explanatory factors. Results: The risk of GERD in those with asthma was OR (odds ratio) 1.52 (95% CI 1.38, 1.68), hay fever OR 1.22 (95%CI 1.12, 1.34) and eczema OR 1.23 (95%CI 1.10, 1.38). Adjusting for affective traits completely attenuated the comorbidity associations for hay fever and eczema with GERD, and partly for asthma with GERD. Co-twin control associations attenuated suggesting a shared cause for both GERD and atopic diseases. For example, all twins adjOR 1.32 (95%CI 1.00, 1.74), 0.97 (95% CI 0.76–1.23) and 1.11 (95%CI 0.85–1.45) for self-report asthma, hay fever and eczema with GERD respectively. Conclusions: GERD is a common comorbidity in adults with asthma, hay fever and/or eczema. We found evidence for shared mechanisms suggesting common underlying causes that may involve affective traits requiring further investigation.

Published
2022
Full Text
View/download PDF

18. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations:an observational study

Author

Magnúsdóttir, Ingibjörg, Lovik, Anikó, Unnarsdóttir, Anna Bára, McCartney, Daniel, Ask, Helga, Kõiv, Kadri, Christoffersen, Lea Arregui Nordahl, Johnson, Sverre Urnes, Hauksdóttir, Arna, Fawns-Ritchie, Chloe, Helenius, Dorte, González-Hijón, Juan, Lu, Li, Ebrahimi, Omid V., Hoffart, Asle, Porteous, David J., Fang, Fang, Jakobsdóttir, Jóhanna, Lehto, Kelli, Andreassen, Ole A., Pedersen, Ole B.V., Aspelund, Thor, Valdimarsdóttir, Unnur Anna, Magnúsdóttir, Ingibjörg, Lovik, Anikó, Unnarsdóttir, Anna Bára, McCartney, Daniel, Ask, Helga, Kõiv, Kadri, Christoffersen, Lea Arregui Nordahl, Johnson, Sverre Urnes, Hauksdóttir, Arna, Fawns-Ritchie, Chloe, Helenius, Dorte, González-Hijón, Juan, Lu, Li, Ebrahimi, Omid V., Hoffart, Asle, Porteous, David J., Fang, Fang, Jakobsdóttir, Jóhanna, Lehto, Kelli, Andreassen, Ole A., Pedersen, Ole B.V., Aspelund, Thor, and Valdimarsdóttir, Unnur Anna

Abstract

BACKGROUND: Long-term mental and physical health consequences of COVID-19 (long COVID) are a persistent public health concern. Little is still known about the long-term mental health of non-hospitalised patients with COVID-19 with varying illness severities. Our aim was to assess the prevalence of adverse mental health symptoms among individuals diagnosed with COVID-19 in the general population by acute infection severity up to 16 months after diagnosis. METHODS: This observational follow-up study included seven prospectively planned cohorts across six countries (Denmark, Estonia, Iceland, Norway, Sweden, and the UK). Participants were recruited from March 27, 2020, to Aug 13, 2021. Individuals aged 18 years or older were eligible to participate. In a cross-sectional analysis, we contrasted symptom prevalence of depression, anxiety, COVID-19-related distress, and poor sleep quality (screened with validated mental health instruments) among individuals with and without a diagnosis of COVID-19 at entry, 0-16 months from diagnosis. In a cohort analysis, we further used repeated measures to estimate the change in mental health symptoms before and after COVID-19 diagnosis. FINDINGS: The analytical cohort consisted of 247 249 individuals, 9979 (4·0%) of whom were diagnosed with COVID-19 during the study period. Mean follow-up was 5·65 months (SD 4·26). Participants diagnosed with COVID-19 presented overall with a higher prevalence of symptoms of depression (prevalence ratio [PR] 1·18 [95% CI 1·03-1·36]) and poorer sleep quality (1·13 [1·03-1·24]) but not symptoms of anxiety (0·97 [0·91-1·03]) or COVID-19-related distress (1·05 [0·93-1·20]) compared with individuals without a COVID-19 diagnosis. Although the prevalence of depression and COVID-19-related distress attenuated with time, individuals diagnosed with COVID-19 but never bedridden due to their illness were consistently at lower risk of depression (PR 0·83 [95% CI 0·75-0·91]) and anxiety (0·77 [0·63-0·94]) than th

Published
2022

19. Cohort Profile:COVIDMENT: COVID-19 cohorts on mental health across six nations

Author

Unnarsdóttir, Anna Bára, Lovik, Anikó, Fawns-Ritchie, Chloe, Ask, Helga, Kõiv, Kadri, Hagen, Kristen, Didriksen, Maria, Christoffersen, Lea Arregui Nordahl, Garðarsson, Alexander Berg, McIntosh, Andrew, Kähler, Anna K, Campbell, Archie, Hauksdóttir, Arna, Erikstrup, Christian, Mikkelsen, Dorte Helenius, Altschul, Drew, Thordardottir, Edda Bjork, Frans, Emma Maria, Kvale, Gerd, Tómasson, Gunnar, Kariis, Hanna Maria, Jónsdóttir, Harpa Lind, Rúnarsdóttir, Harpa, Magnúsdóttir, Ingibjörg, Eid, Jarle, Jakobsdóttir, Jóhanna, Nielsen, Kaspar René, Kaspersen, Kathrine Agergård, Milani, Lili, Trogstad, Lill-Iren Schou, Yi, Lu, Bruun, Mie Topholm, Sullivan, Patrick F, Magnus, Per Minor, Shen, Qing, Nesvåg, Ragnar, Brandlistuen, Ragnhild E, Mägi, Reedik, Ostrowski, Sisse Rye, Løkhammer, Solveig, Solem, Stian, Reichborn-Kjennerud, Ted, Hansen, Thomas Folkmann, Werge, Thomas, Aspelund, Thor, Porteous, David J, Fang, Fang, Lehto, Kelli, Andreassen, Ole A, Pedersen, Ole Birger Vesterager, Hellard, Stephanie Le, Valdimarsdóttir, Unnur A, Unnarsdóttir, Anna Bára, Lovik, Anikó, Fawns-Ritchie, Chloe, Ask, Helga, Kõiv, Kadri, Hagen, Kristen, Didriksen, Maria, Christoffersen, Lea Arregui Nordahl, Garðarsson, Alexander Berg, McIntosh, Andrew, Kähler, Anna K, Campbell, Archie, Hauksdóttir, Arna, Erikstrup, Christian, Mikkelsen, Dorte Helenius, Altschul, Drew, Thordardottir, Edda Bjork, Frans, Emma Maria, Kvale, Gerd, Tómasson, Gunnar, Kariis, Hanna Maria, Jónsdóttir, Harpa Lind, Rúnarsdóttir, Harpa, Magnúsdóttir, Ingibjörg, Eid, Jarle, Jakobsdóttir, Jóhanna, Nielsen, Kaspar René, Kaspersen, Kathrine Agergård, Milani, Lili, Trogstad, Lill-Iren Schou, Yi, Lu, Bruun, Mie Topholm, Sullivan, Patrick F, Magnus, Per Minor, Shen, Qing, Nesvåg, Ragnar, Brandlistuen, Ragnhild E, Mägi, Reedik, Ostrowski, Sisse Rye, Løkhammer, Solveig, Solem, Stian, Reichborn-Kjennerud, Ted, Hansen, Thomas Folkmann, Werge, Thomas, Aspelund, Thor, Porteous, David J, Fang, Fang, Lehto, Kelli, Andreassen, Ole A, Pedersen, Ole Birger Vesterager, Hellard, Stephanie Le, and Valdimarsdóttir, Unnur A

Published
2022

21. Cohort Profile: COVIDMENT: COVID-19 cohorts on mental health across six nations

Author

Unnarsdóttir, Anna Bára, primary, Lovik, Anikó , additional, Fawns-Ritchie, Chloe, additional, Ask, Helga, additional, Kõiv, Kadri, additional, Hagen, Kristen, additional, Didriksen, Maria, additional, Christoffersen, Lea Arregui Nordahl, additional, Garðarsson, Alexander Berg, additional, McIntosh, Andrew, additional, Kähler, Anna K, additional, Campbell, Archie, additional, Hauksdóttir, Arna, additional, Erikstrup, Christian, additional, Mikkelsen, Dorte Helenius, additional, Altschul, Drew, additional, Thordardottir, Edda Bjork, additional, Frans, Emma Maria, additional, Kvale, Gerd, additional, Tómasson, Gunnar, additional, Kariis, Hanna Maria, additional, Jónsdóttir, Harpa Lind, additional, Rúnarsdóttir, Harpa, additional, Magnúsdóttir, Ingibjörg, additional, Eid, Jarle, additional, Jakobsdóttir, Jóhanna, additional, Nielsen, Kaspar René, additional, Kaspersen, Kathrine Agergård, additional, Milani, Lili, additional, Trogstad, Lill-Iren Schou, additional, Yi, Lu, additional, Bruun, Mie Topholm, additional, Sullivan, Patrick F, additional, Magnus, Per Minor, additional, Shen, Qing, additional, Nesvåg, Ragnar, additional, Brandlistuen, Ragnhild E, additional, Mägi, Reedik, additional, Ostrowski, Sisse Rye, additional, Løkhammer, Solveig, additional, Solem, Stian, additional, Reichborn-Kjennerud, Ted, additional, Hansen, Thomas Folkmann, additional, Werge, Thomas, additional, Aspelund, Thor, additional, Porteous, David J, additional, Fang, Fang, additional, Lehto, Kelli, additional, Andreassen, Ole A, additional, Pedersen, Ole Birger Vesterager, additional, Hellard, Stephanie Le, additional, and Valdimarsdóttir, Unnur A, additional

Published
2021
Full Text
View/download PDF

25. Additional file 1 of Age-dependent effects of body mass index across the adult life span on the risk of dementia: a cohort study with a genetic approach

Author

Karlsson, Ida K., Lehto, Kelli, Gatz, Margaret, Reynolds, Chandra A., and Aslan, Anna K. Dahl

Abstract

Additional file 1. Supplementary information about BMI data cleaning, Dementia data in the Swedish Twin Registry, and PGS calculation in the Swedish Twin Registry. Table S1. Age group characteristics for the analysis sample. Table S2. ICD codes used to identify dementia. Table S3. ATC-codes for identification of dementia medication. Table S4. Risk of incident dementia in relation to 5 units higher body mass index measured at different age categories in the Swedish Twin Registry and the Health and Retirement Study, stratified by sex. Table S5. Risk of incident dementia in relation to 5 units higher body mass index measured at different age categories in the Health and Retirement Study, stratified by ethnicity. Table S6. Risk of incident dementia in relation to being underweight, overweight, or obese at different age categories in the Swedish Twin Registry and the Health and Retirement Study. Table S7. Cause specific hazard rate ratios of dementia in relation to 5 units higher body mass index measured at different age categories in the Swedish Twin Registry and the Health and Retirement Study. Figure S1. Flow chart of the sample. Figure S2. Collections of BMI information in the Swedish Twin Registry.

Published
2020
Full Text
View/download PDF

32. Association of depression and use of antidepressants with dementia and alzheimer’s disease genetic risk

Author

Ojalo, Triinu, Lehto, Kelli, juhendaja, Tartu Ülikool. Sotsiaalteaduste valdkond, and Tartu Ülikool. Psühholoogia instituut

Subjects
antikolinergilised antidepressandid, dementsus, antidepressants, depression, matched case-control study, magistritööd, sobitatud juht-kontrolluuring, alzheimer’s disease genetic risk score, depressioon, alzheimeri tõve geneetiline riskiskoor, anticholinergic antidepressants, antidepressandid, dementia
Abstract

Rahvastiku vananemisega on maailmas kasvanud dementsuse levimus. Dementsuse etioloogia ei ole täpselt teada, kuid arvatakse, et selle tekkes on kompleksselt seotud modifitseerimatud bioloogilised ja modifitseeritavad elustiilifaktorid. Varasemates uuringutes on leitud, et hilisema ea depressioon ja antikolinergiliste antidepressantide tarvitamine tõstavad oluliselt dementsuse riski. Käesoleva uuringu eesmärgiks oli uurida Eesti Geenivaramu valimil, kuidas ennustavad depressioon ja antidepressantide kasutus dementsust ja kas depressiooni diagnoos muudab Alzheimeri tõve geneetilise riskiskoori seost dementsusega. Juht-kontrolluuringus sobitati 1026-le dementsuse juhule soo ja vanuse järgi randomiseeritult kolm kontrollisikut (koguvalim n = 4104) ja dementsuse suhtelise tõenäosuse leidmiseks seoses riskifaktoritega viidi läbi logistilised regressioonid. Uuringu tulemustes leiti, et depressioon ja antidepressantide (k.a antikolinergiliste) tarvitamine tõstsid märkimisväärselt dementsuse suhtelist tõenäosust, sealjuures kontrollides teiste teadaolevate dementsuse riskitegurite suhtes (suitsetamise staatus, haridustase, KMI, kardiovaskulaarsed haigused), mis pakub täiendavat tõendust varasemates uuringutes leitud tulemustele. Lisaks leiti, et depressioon tõstis dementsuse suhtelist tõenäosust Alzheimeri tõve geneetilise riskifaktori kõigis kvartiilides võrreldes depressiooni puudumisega, mis viitab võimalusele, et depressiooni ennetuse ja ravimisega on võimalik geneetilise riski mõju vähendada.

Published
2021

33. COVID-19 illness severity and 2-year prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and Denmark.

Author

Shen Q, Joyce EE, Ebrahimi OV, Didriksen M, Lovik A, Sævarsdóttir KS, Magnúsdóttir I, Mikkelsen DH, Unnarsdóttir AB, Hauksdóttir A, Hoffart A, Kähler AK, Thórdardóttir EB, Eythórsson E, Frans EM, Tómasson G, Ask H, Hardardóttir H, Jakobsdóttir J, Lehto K, Lu L, Andreassen OA, Sullivan PF, Pálsson R, Erikstrup C, Ostrowski SR, Werge T, Aspelund T, Pedersen OBV, Johnson SU, Fang F, and Valdimarsdóttir UA

Abstract

Background: Although the persistence of physical symptoms after SARS-CoV-2 infection is a major public health concern, evidence from large observational studies beyond one year post diagnosis remain scarce. We aimed to assess the prevalence of physical symptoms in relation to acute illness severity up to more than 2-years after diagnosis of COVID-19., Methods: This multinational study included 64,880 adult participants from Iceland, Sweden, Denmark, and Norway with self-reported data on COVID-19 and physical symptoms from April 2020 to August 2022. We compared the prevalence of 15 physical symptoms, measured by the Patient Health Questionnaire (PHQ-15), among individuals with or without a confirmed COVID-19 diagnosis, by acute illness severity, and by time since diagnosis. We additionally assessed the change in symptoms in a subset of Swedish adults with repeated measures, before and after COVID-19 diagnosis., Findings: During up to 27 months of follow-up, 34.5% participants (22,382/64,880) were diagnosed with COVID-19. Individuals who were diagnosed with COVID-19, compared to those not diagnosed, had an overall 37% higher prevalence of severe physical symptom burden (PHQ-15 score ≥15, adjusted prevalence ratio [PR] 1.37 [95% confidence interval [CI] 1.23-1.52]). The prevalence was associated with acute COVID-19 severity: individuals bedridden for seven days or longer presented with the highest prevalence (PR 2.25 [1.85-2.74]), while individuals never bedridden presented with similar prevalence as individuals not diagnosed with COVID-19 (PR 0.92 [0.68-1.24]). The prevalence was statistically significantly elevated among individuals diagnosed with COVID-19 for eight of the fifteen measured symptoms: shortness of breath, chest pain, dizziness, heart racing, headaches, low energy/fatigue, trouble sleeping, and back pain. The analysis of repeated measurements rendered similar results as the main analysis., Interpretation: These data suggest an elevated prevalence of some, but not all, physical symptoms during up to more than 2 years after diagnosis of COVID-19, particularly among individuals suffering a severe acute illness, highlighting the importance of continued monitoring and alleviation of these targeted core symptoms., Funding: This work was mainly supported by grants from NordForsk (COVIDMENT, grant number 105668 and 138929) and Horizon 2020 (CoMorMent, 847776). See Acknowledgements for further details on funding., Competing Interests: OAA receives support from the NordForsk (grant number 105668 COVIDMENT) and the European Union’s Horizon 2020 Research and Innovation Programme (Grant 847776; CoMorMent). OAA declares receiving grants or contracts from NIH NIMN Award (R01MH123724-01, 1R01MH124839, 1R01MH129742, 1R01MH129858-01A1), Research Council of Norway (RCN grants 223273, 296030, 300309, 324252), the South-East Norway Health Authority (grant 2017-112, 2022-073), European Union’s Horizon 2020 Research and Innovation Programme (Grant 964874 REALMENT), EEA-RO-NO-2018-0535, and KG Jebsen Stiftelsen (grants SKGJ-MED-008 and SKGJ-MED-021). OAA receives consulting fees from Biogen, Cortechs.ai and Milken. OAA gets Speaker’s honorarium from Janssen, Lundbeck and Sunovion, and has a patent on Intranasal Administration (US20160310683 A1). OAA participated in advisory board as National PI for JANSSEN trial depression, MAPS trial PTSD and BI trial schizophrenia. OAA declares having stock at Cortechs.ai. RP receives grant of Excellence, Icelandic Research Fund. RP declares to be the vice president at UEMS Section of Internal Medicine, a board member of the Icelandic Society of Internal Medicine, and is the president of the Icelandic Transplantation Society. EF received a payment for keynote lecture from Astra Zeneca. SUJ is a leader in Metacognitive Therapy Institute Norwegian Branch. FF receives support from the NordForsk (grant number 105668 and 138929 COVIDMENT) and the Horizon 2020 (Grant 847776; CoMorMent). UAV receives support from the NordForsk (grant number 105668 and 138929 COVIDMENT) and the Horizon 2020 (Grant 847776; CoMorMent). AL declares to receive Fredrik and Ingrid Thuring Foundation. OBVP receives Independent Research Fund Denmark (0214-00127B). QS declares receiving support from the Outstanding Clinical Discipline Project of Shanghai Pudong (Grant No.: PWYgy2021-02) and the Fundamental Research Funds for the Central Universities. PFS declares receiving funding from the Swedish Research Council (Vetenskapsrådet, award D0886501). PFS also receives consulting fees, participating on a data safety monitoring board or advisory board, and holds stock or stock options, from Neumora Therapeutics. All other authors declare no competing interests., (© 2023 The Author(s).)

Published
2023
Full Text
View/download PDF

34. Cohort Profile: COVIDMENT: COVID-19 cohorts on mental health across six nations.

Author

Unnarsdóttir AB, Lovik A, Fawns-Ritchie C, Ask H, Kõiv K, Hagen K, Didriksen M, Christoffersen LAN, Garðarsson AB, McIntosh A, Kähler AK, Campbell A, Hauksdóttir A, Erikstrup C, Mikkelsen DH, Altschul D, Thordardottir EB, Frans EM, Kvale G, Tómasson G, Kariis HM, Jónsdóttir HL, Rúnarsdóttir H, Magnúsdóttir I, Eid J, Jakobsdóttir J, Nielsen KR, Kaspersen KA, Milani L, Trogstad LS, Yi L, Bruun MT, Sullivan PF, Magnus PM, Shen Q, Nesvåg R, Brandlistuen RE, Mägi R, Ostrowski SR, Løkhammer S, Solem S, Reichborn-Kjennerud T, Hansen TF, Werge T, Aspelund T, Porteous DJ, Fang F, Lehto K, Andreassen OA, Pedersen OBV, Hellard SL, and Valdimarsdóttir UA

Subjects
Cohort Studies, Humans, Mental Health, COVID-19, Mental Disorders epidemiology
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results